Montag, 18.10.2021 17:45 von GlobeNewswire | Aufrufe: 467

Virbac: excellent revenue growth of 21.2% at the end of September at comparable exchange rates and scope (+16.4% at constant rates and real scope), driven by a very solid third-quarter performance again in all areas

Wirtschaftsnachrichten (Symbolbild). pixabay.com




KEY FIGURES
Revenue
Year-to-date September 30, 2021
 
€817.7 million
At constant exchange rates
and scope1
 
+21.2% including

companion animals +24.3%
food producing animals +15.0%
Growth adjusted
at constant exchange rates
 
+16.4%

Overall
change
 
+14.5%
+19.3% excl. Sentinel

1 Change at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the exchange rate used is the previous financial year’s), and excluding change in scope, calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous year, and excluding sales of Sentinel, a product that was sold on July 1, 2020, over the first two half-years in question.


Quarterly consolidated revenue
Our third-quarter revenue reached €288.2 million, or a steep 22.4% increase with respect to the same period in 2020. At constant exchange rates, growth was +21%, mainly driven by the remarkable performance of Europe and the United States and the good performance of other areas, particularly Chile, which experienced a rebound and growth during the quarter. In Europe, all countries contributed to our growth, particularly the United Kingdom, France, the area’s export activity, Germany and Benelux, which performed exceptionally well in the companion animal segment (vaccines, petfood, and specialty products). The United States saw very strong growth during the quarter, particularly thanks to dental, specialties and parasiticides ranges and to the contribution of recently launched products (Clomicalm, Itrafungol, iVet petfood, Milbehart, etc.). Latin America benefited from Chile’s performance, which contributed half of the area’s growth during the quarter, and from the strong momentum in Brazil and Mexico. Finally, in Asia-Pacific, Australia drives most of the quarter’s growth, thanks to products for ruminants (vaccines, parasiticides and food supplements). India, China and Japan are down during the period after very strong growth during the first half of the year, and there is a very unfavorable baseline effect for India, compared to the third quarter of 2020.


Cumulative consolidated revenue at the end of September

Our revenue through to the end of September was €817.7 million, compared with €713.9 million, representing an overall increase of 19.3% excluding Sentinel (+14.5% at real scope) compared with the same period in 2020. Excluding the unfavorable impact of exchange rates, revenue rose by 21.2% excluding Sentinel (+16.4% at real scope).

Kurse

  
366,00
-2,92%
Virbac SA Realtime-Chart
Werbung

Weiter abwärts?

  
Kurzfristig positionieren in Virbac SA
Ask: 7,71
Hebel: 5,91
mit moderatem Hebel
Morgan Stanley
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: MD11S3,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
CONSOLIDATED FIGURES
Non-audited figures
in millions of euros
2021 2020 Growth Growth
at constant exchange rates 1
Growth
at constant exchange rates and scope of consolidation 1
First-quarter revenue 266.5 247.7 +7.6% +12.3% +22.6%
Second-quarter revenue 262.9 230.6 +14.0% +15.8% +20.0%
Third-quarter revenue 288.2 235.6 +22.4% +21.0% +21.0%
Revenue at the end of September 817.7 713.9 +14.5% +16.4% +21.2%
Revenue excluding Sentinel 810.1 678.8 +19.3% +21.2% +21.2%



A lifelong commitment to animal health
At Virbac, we make innovative solutions available to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services can diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving the quality of life of animals and to shaping the future of animal health together.


Virbac: NYSE Euronext - compartment A – ISIN code: FR0000031577 / MNEMO: VIRP
Financial Affairs Department: tel. 04 92 08 71 32 - email: finances@virbac.com - Website: corporate.virbac.com

Attachment


Werbung
Mehr Nachrichten zur Red Electrica Aktie kostenlos abonnieren
E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptieren Sie die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.

Andere Nutzer interessierte auch dieser Artikel: